This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen (PAPRIKA)

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: December 28, 2006
Last updated: May 3, 2016
Last verified: May 2016
The purpose of this study is to compare the efficacy and the safety Larotaxel administered as single agent every 3 weeks to continuous administration of 5-FU every 3 weeks, in patients with advanced pancreatic cancer (non operable in a curative intent, locally recurrent or metastatic) previously treated with gemcitabine based therapy.

Condition Intervention Phase
Pancreatic Neoplasms Drug: Larotaxel (XRP9881) Drug: 5-Fluorouracil Drug: Capecitabine Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label Multi-Center Study Of Single Agent Larotaxel (XRP9881) Compared To Continuous Administration of 5-FU For The Treatment Of Patients With Advanced Pancreatic Cancer Previously Treated With A Gemcitabine-Containing Regimen

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause [ Time Frame: study period ]

Secondary Outcome Measures:
  • Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms; [ Time Frame: study period ]

Enrollment: 408
Study Start Date: December 2006
Study Completion Date: November 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Larotaxel (XRP9881) Drug: Larotaxel (XRP9881)
administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
Active Comparator: 5-Fluorouracil or capecitabine
Each Investigator must choose either IV 5-FU or oral capecitabine regimen before the first participant begins the study and has to consistently use the chosen regimen throughout the study for all participants treated at her/his site.
Drug: 5-Fluorouracil
administered as IV infusion from Day 1 to Day 4
Drug: Capecitabine
administered orally from Day 1 to Day 14 q3w


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced (non operable in a curative intent, locally recurrent or metastatic disease) Cytologically or histologically proven epithelial cancer (adenocarcinoma) of the exocrine pancreas.
  • Patient must be previously treated with a systemic gemcitabine based regimen
  • Adequate bone marrow, kidney and liver functions

Exclusion Criteria:

  • ECOG performance status (PS) of 2-3-4.
  • Prior locoregional radiotherapy for pancreatic cancer.
  • Symptomatic brain metastases or leptomeningeal disease.
  • Any serious intercurrent infections, uncontrolled cardiac or gastro-intestinal diseases.
  • Other concurrent malignancy
  • Other protocol-defined exclusion/inclusion criteria may apply
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00417209

  Show 21 Study Locations
Sponsors and Collaborators
Study Director: ICD Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT00417209     History of Changes
Other Study ID Numbers: EFC6596
EUDRACT: 2006-003086-14
Study First Received: December 28, 2006
Last Updated: May 3, 2016

Keywords provided by Sanofi:
advanced pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on September 18, 2017